Acrivon TherapeuticsACRV
Market Cap: 274M
About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Employees: 61
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
46% more capital invested
Capital invested by funds: $74.4M [Q4 2023] → $109M (+$34.6M) [Q1 2024]
15% more funds holding
Funds holding: 41 [Q4 2023] → 47 (+6) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
0.23% less ownership
Funds ownership: 68.93% [Q4 2023] → 68.7% (-0.23%) [Q1 2024]
Research analyst outlook
10 Wall Street Analysts provided 1 year price forecasts over the past 6 months
10 analyst ratings
BMO Capital Etzer Darout | 182%upside $25 | Outperform Reiterated | 15 May 2024 |
HC Wainwright & Co. Emily Bodnar | 148%upside $22 | Buy Maintained | 14 May 2024 |
BMO Capital Etzer Darout | 182%upside $25 | Outperform Maintained | 26 Apr 2024 |
JMP Securities Silvan Tuerkcan | 92%upside $17 | Market Outperform Maintained | 25 Apr 2024 |
Piper Sandler Joseph Catanzaro | 239%upside $30 | Overweight Maintained | 25 Apr 2024 |